Semaglutide for Weight Loss in Lisle, IL
Medically supervised semaglutide protocols, prescribed and monitored by our clinical team. Custom dosing, weekly check-ins, real accountability.
Book a Free ConsultationSemaglutide is a GLP-1 receptor agonist FDA-approved for chronic weight management (under the brand name Wegovy) and type 2 diabetes (Ozempic, Rybelsus). Developed by Novo Nordisk, it is administered as a once-weekly subcutaneous injection.
| Generic name | Semaglutide |
| Brand names | Wegovy (weight loss), Ozempic (type 2 diabetes), Rybelsus (oral type 2 diabetes) |
| Manufacturer | Novo Nordisk |
| FDA approval (weight loss) | June 2021 |
| Mechanism | GLP-1 receptor agonist |
| Administration | Once-weekly subcutaneous injection (Wegovy, Ozempic) or daily oral tablet (Rybelsus) |
| Typical dose range | 0.25 mg to 2.4 mg (titrated over months) |
How Semaglutide Works
GLP-1 receptor activation
Semaglutide mimics the natural hormone glucagon-like peptide-1 (GLP-1), which is released in the gut after eating. Activating these receptors triggers a chain of appetite and metabolic effects.
Reduced appetite
Semaglutide acts on appetite centers in the brain to reduce hunger and increase satiety. Most patients report eating less and feeling full sooner.
Slower gastric emptying
Semaglutide slows the rate at which the stomach empties, prolonging the feeling of fullness after meals and reducing blood sugar spikes.
Improved blood sugar control
Semaglutide stimulates insulin release when blood sugar is elevated and reduces glucagon production, which improves overall glucose regulation. This is why the same medication is used for both weight loss and type 2 diabetes.
What Research Shows About Semaglutide
In the STEP-1 trial (published in the New England Journal of Medicine, 2021), adults with overweight or obesity who took 2.4 mg semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group.
Subsequent STEP trials confirmed these results in different populations. The SUSTAIN cardiovascular outcomes trial also found that semaglutide reduces the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes.
Semaglutide was the first GLP-1 medication to demonstrate consistent weight loss above 10% in large randomized trials and remains one of the most-studied weight loss medications available.
Semaglutide vs Tirzepatide
Semaglutide and tirzepatide are the two most prescribed GLP-1 weight loss medications. Both are once-weekly injections, but their mechanisms and efficacy differ.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 agonist only | Dual GIP / GLP-1 agonist |
| Average weight loss (highest dose) | ~15% | ~22.5% |
| FDA approval (weight loss) | 2021 (Wegovy) | 2023 (Zepbound) |
| Brand names | Wegovy, Ozempic, Rybelsus | Zepbound, Mounjaro |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Administration | Weekly injection or daily oral | Weekly injection |
Semaglutide at Defiant Health
Free Consultation
Meet with our medical team to discuss your goals, medical history, and whether semaglutide is right for you. No commitment.
Bloodwork & Body Scan
Comprehensive bloodwork to confirm eligibility, plus a 3D body composition scan to establish your starting baseline.
Custom Protocol
Personalized semaglutide dosing and titration schedule built around your labs, body composition, and goals.
Ongoing Support
Weekly nurse check-ins, monthly body composition scans, and real-time dose adjustments as you progress.
Custom GLP-1 Protocols from $295/mo
Includes medication, provider oversight, weekly nurse check-ins, and monthly body composition scans. Defiant members save 20%.
Book Your ConsultationWho Semaglutide Is For
- + Adults with a BMI of 30 or higher
- + Adults with a BMI of 27 or higher with at least one weight-related condition (high blood pressure, type 2 diabetes, sleep apnea, cardiovascular disease)
- + People who have tried lifestyle changes without sustained results
- + People who are committed to lifestyle support alongside medication
Who Semaglutide Is Not For
- − Pregnant or breastfeeding individuals
- − Personal or family history of medullary thyroid carcinoma
- − Multiple endocrine neoplasia syndrome type 2 (MEN-2)
- − Severe gastrointestinal disease, including gastroparesis
- − Active pancreatitis or history of pancreatitis
Our medical team reviews your full history before prescribing. This is not an exhaustive list of contraindications.
Semaglutide Questions
Plain-language answers to the most common questions about semaglutide treatment at Defiant in Lisle, IL.
Semaglutide Weight Loss in Chicago’s Western Suburbs
Defiant Health offers semaglutide weight loss programs at our Lisle, IL clinic — serving Naperville, Downers Grove, Wheaton, Bolingbrook, Lombard, and the greater Chicago western suburbs.
References
- 1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. View source →
- 2. U.S. Food and Drug Administration. FDA approves new drug treatment for chronic weight management. June 4, 2021. View source →
- 3. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. View source →
This page is for educational purposes only and does not constitute medical advice. Semaglutide is a prescription medication. Consult a licensed healthcare provider for advice specific to your situation. Defiant Health does not bill insurance directly.